PSAP 2021 Book 1 (*Infectious Diseases*)
Release date: January 15, 2021
BCPS test deadline: 11:59 p.m. (Central) on July 15, 2021.
ACPE test deadline: 11:59 p.m. (Central) on January 15, 2024.

 Continuing Pharmacy Education (CPE) Credit: The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of CPE.

PSAP Target Audience: The target audience for PSAP 2021 Book 1 (Infectious Diseases) is pharmacotherapy specialists and advanced level clinical pharmacists encountering patients with infectious diseases.

Module I (5.0 CPE): 0217-0000-21-002-H01-P

Chapter: New Antimicrobial Agents
Learning Objectives
1. Distinguish the pharmacology, spectrum of activity, and practical applications of ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and cefiderocol.
2. Demonstrate similarities and differences in the pharmacology, spectrum of activity, and practical applications of omadacycline, eravacycline, and plazomicin.
3. Apply knowledge of new antimicrobial agents to select optimal pharmacotherapy for patient-specific clinical scenarios and formulary considerations.

Chapter: Antimicrobial Dosing in Special Populations: CRRT and Obesity
Learning Objectives
1. Evaluate a renal replacement therapy plan and anticipate its effect on antimicrobial clearance.
2. Design an antimicrobial dosing strategy for a critically ill patient receiving continuous renal replacement therapy.
3. Justify the dosing weight/strategy for various antimicrobials in a patient with obesity with an infectious disease.

Module II (7.5 CPE): 0217-0000-21-003-H01-P

Chapter: Multidrug-Resistant Infections
Learning Objectives (A)
1. Assess rapid diagnostic technologies and clinical resources for use in the detection and treatment of multidrug-resistant (MDR) infections.

2. Develop a therapeutic regimen for a patient with an MDR gram-positive infection on the basis of antimicrobial susceptibility profile and infection-related and host factors.

3. Evaluate the role of antimicrobial agents with activity against selected nonfermenting gram-negative pathogens as empiric and directed management.

4. Evaluate antimicrobial agents in clinical development.

5. Justify the use of integrative campaigns to reduce the development and spread of MDR infections within institutional or ambulatory care settings.

Chapter: Cytomegalovirus Infection in the Immunocompromised Patient

Learning Objectives

1. Evaluate immunocompromised patients for direct and indirect effects of cytomegalovirus (CMV) infection.

2. Develop prophylaxis and/or treatment for CMV infection after transplantation (organ-specific) on the basis of patient characteristics.

3. Design universal or preemptive prophylactic regimens and regimens for treating CMV disease on the basis of patient-specific characteristics and CMV donor/recipient matching.

4. Apply resistance panel results in order to initiate an appropriate antiviral treatment regimen after diagnosis of CMV disease.

Chapter: Infection in Patients Receiving Biologic Agents for Inflammatory Diseases

Learning Objectives

1. Evaluate for infectious diseases in patients receiving biologic therapy for inflammatory and autoimmune disorders.

2. Develop a monitoring plan and preventive strategies for patients receiving biologic response modifiers.

3. Evaluate individual patients receiving biologic agents for infection and design a management plan.

Module III (5.0 CPE): 0217-0000-21-004-H01-P

Interactive Case: Interactive Case: Penicillin Allergy

Learning Objectives

1. Evaluate the impact of penicillin allergies on infectious diseases outcomes and antimicrobial selection.

2. Distinguish between various types of penicillin allergy reactions and presentations.

3. Evaluate various penicillin allergy assessment and intervention options.

4. Develop treatment strategies in patient cases with self-reported penicillin allergies to enhance delabeling.

Interactive Case: Interactive Case: Strategies for Antimicrobial Optimization

Learning Objectives
1. Assess the use of antibiotic optimization strategies as antimicrobial stewardship initiatives.
2. Analyze the data supporting the use of each optimization strategy to determine its clinical effectiveness and place in practice.
3. Evaluate patient profiles to determine which optimization strategies are appropriate to use to improve patient outcomes.

Statistics in Practice: Statistics in Practice: Survival Analysis and Common Applications

Learning Objectives
1. Assess data used in survival analysis, including censored observations.
2. Interpret results from Kaplan-Meier curves, Cox proportional hazards models, and log-rank tests.
3. Determine the most appropriate survival analysis to perform, including when the assumption of proportional hazards is not met.